Drake, Christopher L.
Kalmbach, David A.
Cheng, Philip
Ahmedani, Brian K.
Peterson, Edward L.
Joseph, Christine L. M.
Roth, Thomas
Kidwell, Kelley M.
Sagong, Chaewon
Funding for this research was provided by:
National Institute of Mental Health (R56MH115150, R01MH122636)
Article History
Received: 16 August 2022
Accepted: 19 October 2022
First Online: 1 December 2022
Declarations
:
: This study is approved by the local IRB, and all participants provided informed consent prior to participating.
: The authors provide consent for the publication of this study protocol.
: Dr. Drake has received research support from Apnimed and Proctor & Gamble. Dr. Cheng has received research support from Harmony Biosciences. Dr. Thomas Roth has acted as a consultant for Abbott, Acadia, Acoglix, Actelion, Alchemers, Alza, Ancil, Arena, Astra Zeneca, Aventis, AVER, BMS, BTG, Cephalon, Cypress, Dove, Elan, Eli Lilly, Evotec, Forest, Glaxo Smith Kline, Hypnion, Impax, Intec, Intra-Cellular, Jazz, Johnson & Johnson, King, Lundbeck, McNeil, Medici Nova, Merck & Co., Neurim, Neurocrine, Neurogen, Novartis, Orexo, Organon, Prestwick, Procter-Gamble, Pfizer, Purdue, Resteva, Roche, Sanofi, Schering-Plough, Sepracor, Servier, Shire, Somaxon, Syrex, Takeda, TransOral, Vanda, Vivometrics, Wyeth, Yamanuchi, and Xenoport.